Role of antifungal agents in the treatment of seborrheic dermatitis

American Journal of Clinical Dermatology

Volumn 5, Issue 6, 2004, Pages 417-422

  Gupta, Aditya K ^a,b,c   Nicol, Karyn ^b   Batra, Roma ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BIFONAZOLE; BUTENAFINE; CICLOPIROX; CINNAMIC ACID; FLUCONAZOLE; IMMUNOMODULATING AGENT; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; PIMECROLIMUS; PYRITHIONE ZINC; SELENIUM SULFIDE; SHAMPOO; TACROLIMUS; TEA TREE OIL; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CREAM; HONEY; HUMAN; MALASSEZIA; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; REVIEW; SEBORRHEIC DERMATITIS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; DERMATITIS, SEBORRHEIC; HUMANS; MALASSEZIA; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 12944299764     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405060-00006     Document Type: Review

References (79)

1. Burton JL. Seborrheic dermatitis. In: Wilkinson DS, Ebling FJG, editors. Textbook of dermatology. Oxford: Blackwell Scientific Publications, 1992: 1561-1622
2. Hancox JG, Sheridan SC, Feldman SR, et al. Seasonal variation of dermatologic disease in the USA: a study of office visits from 1990 to 1998. Int J Dermatol 2004; 43(1): 6-11
3. Pierard-Franchimont C, Hermanns JF, Degreef H, et al. From axioms to new insights into dandruff. Dermatology 2000; 200 (2): 93-8
4. Berg M. Epidemiological studies of the influence of sunlight on the skin. Photodermatol 1989; 6: 80-4
5. Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol 1983; 63: 335-9
6. Gueho E, Midgley G, Guillot J. The genus Malassezia with description of four new species. Antonic van Leeuwenhoek 1996; 69: 337-55
7. Nell A, James SA, Bond CJ, et al. Identification and distribution of a novel Malassezia species yeast on normal equine skin. Vet Rec 2002; 150: 395-8
8. Sugita T, Takashima M, Shinoda T, et al. New yeast species, Malassezia dermatis, isolated from patients with atopic dermatitis. J Clin Microbiol 2002; 40: 1363-7
9. Crespo EV, Delgado FV. Malassezia species in skin diseases. Curr Opin Infect Dis 2002; 15: 133-42
10. Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984; 111: 235-42
11. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000; 1: 75-80
12. Watanabe S, Kano R, Sato H, et al. The effects of Malussezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol 2001; 116: 769-73
13. Faergemann J, Bergbrant IM, Dohse M, et al. Seborrhoeic dermatitis and Pityrosporum Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144: 549-56
14. Hay RJ, Graham-Brown RA. Dandruff and seborrhoeic dermatitis: causes and management. Clin Exp Dermatol 1997; 22: 3-6
15. Pierard GE. Seborrheic dermatitis today, gone tomorrow? The link between the biocene and treatment. Dermatology 2003; 206: 187-8
16. Shemer A, Nathansohn N, Kaplan B, et al. Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol 2000; 39: 532-4
17. Segal R, David M, Ingber A, et al. Treatment with bifonazole shampoo for seborrhea and seborrheic dermatitis: a randomized, double-blind study. Acta Derm Venereol 1992; 72: 454-5
18. Shiri J, Amichai B. Treatment of seborrheic dermatitis of the scalp and dandruff with a shampoo containing 1% bifonazole (Agispor shampoo). J Dermatolog Treat 1998; 9: 95-6
19. Zienicke H, Korting HC, Braun-Falco O, et al. Comparative efficacy and safety of bifonazole 1% cream and the corresponding base preparation in the treatment of seborrhoeic dermatitis. Mycoses 1993; 36: 325-31
20. Wigger-Alberti W, Kluge K, Elsner P. Clinical effectiveness and tolerance of climbazole containing dandruff shampoo in patients with seborrheic scalp eczema [in German]. Schweiz Rundsch Med Prax 2001; 90: 1346-9
21. Go IH, Wientjens DPWM, Koster M. A double-blind trial of 1% ketoconazole shampoo versus placebo in the treatment of dandruff. Mycoses 1992; 35: 103-5
22. Pierard-Franchimont C, Pierard GE, Arrese JE, et al. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology 2001; 202: 171-6
23. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol 1995; 132: 441-5
24. Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole: I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol 1987; 116: 213-6
25. Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29: 1008-12
26. Dobrev H, Zissova L. Effect of ketoconazole 2% shampoo on scalp sebum level in patients with seborrhoeic dermatitis. Acta Derm Venereol 1997; 77: 132-4
27. Pierard-Franchimont C, Coffin V, Decroix J, et al. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol 2002; 15: 434-41
28. Shuttleworth D, Squire RA, Boorman GC, et al. Comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) or ketoconazole (2%, Nizoralâ) for the control of dandruff/seborrhoeic dermatitis. J Dermatolog Treat 1998; 9: 157-62
29. Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat 2002; 13: 51-60
30. Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol 1987; 116: 217-21
31. Katsambas A, Antoniou C, Frangouli E, et al. A double-blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream. Br J Dermatol 1989; 121: 353-7
32. Pari T, Pulimood S, Jacob M, et al. Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1998; 10: 89-90
33. Skinner Jr RB, Noah PW, Taylor RM, et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985; 12: 852-6
34. Stratigos J, Antoniou C, Katsambas A, et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. J Am Acad Dermatol 1988; 19: 850-3
35. Ortonne JP, Lacour JP, Vitetta A, et al. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology 1992; 184: 275-80
36. Pierard GE, Pierard-Franchimont C, Van Cutsem J, et al. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol 1991; 30: 806-9
37. Parsad D, Pandhi R, Negi KS, et al. Topical metronidazole in seborrheic dermatitis: a double-blind study. Dermatology 2001; 202: 35-7
38. Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol 1986; 114: 695-700
39. Pierard-Franchimont C, Pierard GE. A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology 2002; 204: 344-7
40. Sheth RA. A comparison of miconazole nitrate and selenium disulfide as antidandruff agents. Int J Dermatol 1983; 22: 123-5
41. Rigopoulos D, Katsambas A, Antoniou C, et al. Facial seborrheic dermatitis treated with fluconazole 2% shampoo. Int J Dermatol 1994; 33: 136-7
42. Faergemann J, Jones JC, Hettler O, et al. Pityrosparum ovule (Malassezia furfur) as the causative agent of seborrhoeic dermatitis: new treatment options. Br J Dermatol 1996; 134 Suppl. 46: 12-5
43. Gupta AK, Yokou M, Arika T, et al. Evaluation of the in vitro and in vivo efficacy of butenafine hydrochloride cream 1% against Malassezia furfur species and seborrheic dermatitis. J Dermatolog Treat 2000; 11: 79-83
44. Aly R, Katz HI, Kempers SE, et al. Ciclopirox gel for seborrheic dermatitis of the scalp. Int J Dermatol 2003; 42 Suppl. 1: 19-22
45. Abeck D. Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int J Dermtol 2004; 43 Suppl. 1: 13-6
46. Altmeyer P, Hoffmann K. Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43 Suppl. 1: 9-12
47. Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43 Suppl. 1: 17-20
48. Shuster S. A phase III, multinational, randomized, double-blind, vehicle-controlled study to assess the efficacy of ciclopirox shampoo for the treatment of seborrheic dermatitis/dandruff of the scalp. Proceedings of the 61st Annual Meeting of the American Academy of Dermatology; 2003 Mar 21-26; San Francisco. J Am Acad Dermatol
49. Vardy DA, Zvulunov A, Tchetov T, et al. A double-blind, placebo-controlled trial of a ciclopirox olamine 1% shampoo for the treatment of scalp seborrheic dermatitis. J Dermatolog Treat 2000; 11: 73-7
50. Dupuy P, Maurette C, Amoric JC, et al. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001; 144: 1033-7
51. Unholzer A, Varigos G, Nicholls D, et al. Ciclopiroxolamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison. Infection 2002; 30: 373-6
52. Crutchfield III CE. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis 2002; 70: 207-8
53. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49: 145-7
54. Marks R, Pearse AD, Walker AP. The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol 1985; 112: 415-22
55. Orentreich N, Taylor EH, Berger RA, et al. Comparative study of two antidandruff preparations. J Pharm Sci 1969; 58: 1279-80
56. Satchell AC, Saurajen A, Bell C, et al. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol 2002; 47: 852-5
57. Al-Waili NS. Therapeutic and prophylactic effects of crude honey on chronic seborrheic dermatitis and dandruff. Eur J Med Res 2001; 6: 306-8
58. Conti-Diaz IA, Civila E, Asconegui F. Treatment of superficial and deep-seated mycoses with oral ketoconazole. Int J Dermatol 1984; 23: 207-10
59. Ford GP, Farr PM, Ive FA, et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603-7
60. Caputo R, Barbareschi M. Itraconazole: new horizons. G Ital Dermatol Venereol 2002; 137: 1-7
61. Scaparro E, Quadri G, Virno G, et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis: a multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001; 144: 854-7
62. Ghannoum MA, Kuhn DM. Voriconazole: better chances for patients with invasive mycoses. Eur J Med Res 2002; 7: 242-56
63. Gupta AK, Einarson TR, Summerbell RC, et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs 1998; 55: 645-74
64. McGrath J, Murphy GM. The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. Drugs 1991; 41: 178-84
65. Elewski BE. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993; 28: S28-34
66. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997; 36: 788-92
67. Chosidow O, Maurette C, Dupuy P. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology 2003; 206: 233-40
68. Faergemann J. Treatment of seborrhoeic dermatitis with oral terbinafine? Lancet 2001 Jul; 358 (9277): 170
69. Nahm WK, Orengo I, Rosen T. The antifungal agent butenafine manifests antiinflammatory activity in vivo. J Am Acad Dermatol 1999; 41: 203-6
70. Abrams BB, Hänel H, Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol 1992; 9: 471-7
71. Gupta AK. Ciclopirox: an overview. Int J Dermatol 2000; 40: 1-7
72. Hanel H, Smith-Kurtz E, Pastowsky S. Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect [in German]. Mycoses 1991; 34 Suppl. 1: 91-3
73. Korting HC, Grundmann-Kollmann M. The hydroxypyridones: a class of antimycotics of its own. Mycoses 1997; 40: 243-7
74. Gupta AK, Skinner AR. Ciclopirox for the treatment of superficial fungal infections: a review. Int J Dermatol 2003; 42 Suppl. 1: 3-9
75. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-41
76. Nakagawa H, Etoh T, Yokota Y, et al. Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin Drug Invest 1996; 12: 245-50
77. Butterfield W, Roberts MM, Dave VK. Sensitivities of Pityrosporum sp. to selected commercial shampoos. Br J Dermatol 1987; 116: 233-5
78. Hammer KA, Carson CF, Riley TV. In vitro susceptibility of Malassezia furfur to the essential oil of Melaleuca alternifolia. J Med Vet Mycol 1997; 35: 375-7
79. Baroni A, De Rosa R, De Rosa A, et al. New strategies in dandruff treatment: growth control of Malassezia ovalis. Dermatology 2000; 201: 332-6